Also trades as: NRXPW (NASDAQ) · $vol 0M
NRXP NASDAQ
NRx Pharmaceuticals, Inc.
1W: -3.0%
1M: -15.0%
3M: -28.0%
YTD: -2.7%
1Y: -20.3%
3Y: -10.5%
5Y: -97.5%
$2.69
+0.14 (+5.29%)
Weekly Expected Move ±7.3%
$2
$2
$2
$3
$3
Credit Risk of going bust: lower than 55% of companies Debt: 1.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.8%), NRx Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.2M against a stock market value of $110.4M.
Distance to default 5.66 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $790K (short-term plus half of long-term), stock volatility 82.7%; Altman Z'' -36.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.8%), NRx Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.2M against a stock market value of $110.4M.
Distance to default 5.66 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $790K (short-term plus half of long-term), stock volatility 82.7%; Altman Z'' -36.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$110.4M
52W Range1.62-5.06
Volume592,936
Avg Volume880,496
Beta2.07
Dividend—
Analyst Ratings
Company Info
CEOJonathan C. Javitt
Employees29
SectorHealthcare
IndustryBiotechnology
IPO Date2017-12-04
Websitenrxpharma.com
1201 Orange Street
Wilmington, DE 19801
US
Wilmington, DE 19801
US
484 254 6134
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Latest News
NRx Defense Systems awarded $11M DARPA prime contract
Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Casper Joseph Michae | A-Award | 100,000 | $2.39 | 2026-01-27 |
| Casper Joseph Michae | 100,000 | $2.39 | 2026-01-27 | |
| B Group, Inc. | 0 | — | 2025-08-18 | |
| Javitt Jonathan C | A-Award | 125,000 | $1.73 | 2025-04-09 |
| McBride Dennis | A-Award | 25,000 | $1.73 | 2025-04-09 |